Connect with us

News Briefs

Study Suggests Psilocybin Can Help Smokers Quit

Published

on

Study Suggests Psilocybin Can Help Smokers Quit

A recent study published by Johns Hopkins University researchers comparing psilocybin to nicotine patches found that participants given a single dose of the psychedelic were six times more likely to abstain from smoking than those given the patch, according to a NPR report.

The study, a randomized trial of 82 smokers, was published this week in JAMA Network. The researchers noted that after a six-month follow-up, about 40% of participants given a psilocybin treatment had quit smoking, while only about 10% of those given the patch had stopped.

The researchers also noted that abstinence rates among those given the psychedelic “were higher than typical treatments, suggesting promise for smoking cessation.”

The study’s lead author and a professor of psychiatry at Johns Hopkins, Matthew Johnson, told NPR he was “surprised by the sheer size of the effect.”

Participants who took psilocybin were given a high dose, according to the report. Additionally, there was no placebo with the test, so everyone given psilocybin was aware they were taking the drug, which the researchers noted could bias the results.

Based in Portland, Oregon, Graham is the editor-in-chief of Ganjapreneur. He has been writing about the legalization landscape since 2012 and has contributed to Ganjapreneur since our official launch in…

Continue Reading

adult use

Texas Lawsuit Seeks to Block Smokable Hemp Products Ban

Published

on

By

Texas Lawsuit Seeks to Block Smokable Hemp Products Ban

A coalition of hemp industry stakeholders and advocacy groups filed a temporary restraining order against the Texas Department of State Health Services (DSHS) and the Texas Health and Human Services Commission on Tuesday, seeking to block recently implemented ban on smoked hemp products, Texas Tribune reports.

Enacted on March 31, the ban bans the sale of cannabis flowers, pre-rolls and vaporizers. DSHS officials targeted the products by updating state regulations to count the cannabinoid THCA — which by itself is not intoxicating, but when decarboxylated (heated or burned), turns into delta-9 THC — toward the maximum THC allowed in hemp products. According to state law, hemp-derived products must not exceed the federal limit of 0.3% THC content.

In their challenge, however, the plaintiffs argue that state officials lacked the authority to issue such sweeping changes.

“Under current Texas law, hemp is defined by its delta-9 THC concentration of no more than 0.3%. These Texas officials and state agencies are clearly trying to create new law in direct opposition to what the Texas legislature intended.” — David Sergi, attorney for the Hemp Coalition, in a press release

Meanwhile, officials also passed new product testing and age verification requirements and significantly raised the state’s hemp licensing fees. The Hemp Industry Coalition is not challenging those changes.

“Texas hemp businesses wholeheartedly support those regulations, as they are under the agency’s authority,” Sergi said in the report. “We’re seeking to stop rules that would effectively end the state’s production of hemp and the sale of hemp products — items the Legislature chose not to ban during recent legislative and special sessions.”

Continue Reading

cannabis policy

Nebraska Bill to Protect Doctors Who Recommend Medical Cannabis Fails

Published

on

By

Nebraska Bill to Protect Doctors Who Recommend Medical Cannabis Fails

There will be no protections provided in Nebraska state law this year for doctors who refer patients to the state’s medical cannabis program after cannabis opponents blocked the legislation from state Sen. John Cavanaugh (R). NTV reports.

legislators voted to approve proposal during early review. However, in subsequent debates, opponents of medical cannabis derailed the bill with amendments that sought to change the intent of the proposal.

With the added changes, Cavanaugh eventually withdrew the bill from consideration, noting that “This bill no longer serves the purpose of ensuring that children have access to medicine.”

“Every amendment that has been introduced to that bill is hostile and an attempt to hijack that bill and go against the will of the voters.” – Cavanaugh, via NTV

Nebraska voters overwhelmingly approved the state’s medical cannabis program in 2024, but rollout has been slow and, for many advocates, frustrating.

Crista Eggers of the Nebraskans Campaign for Medical Marijuana said KETV“If there are no practitioners, there are no patients in this program.”

“What seems to be the purpose of this is to make sure that Nebraska never has a functioning program,” she said.

Meanwhile, the Nebraska Legislature approved last week the first state legislation related to the medical cannabis program. This bill would allow the Nebraska Medical Cannabis Commission to impose new fees on the industry and increase revenue.

Continue Reading

Federal Policy

Medicare Coverage for Some Hemp-Derived Products Now Available

Published

on

By

Medicare Coverage for Some Hemp-Derived Products Now Available

Medicare’s pilot program covering hemp-derived products has officially launched. Under the plan, Medicare providers can be reimbursed up to $500 per patient each year for discussing and offering certain CBD products.

CBD products covered under the plan cannot exceed concentrations of 0.3% delta-9 THC, or more than 3 milligrams of THC per serving. Products must also be third-party tested and meet state and local standards. It excludes patients who have certain medical conditions, including substance use disorder and COPD.

In an April 1 statement, Centers for Medicare & Medicaid Services (CMS) Administrator Mehmet Oz said the agency “is committed to innovation that meets patients’ needs while maintaining strong safeguards and clinical oversight.”

“Under (President Donald Trump’s) leadership, we are expanding the tools available to improve patient health while generating important insights into how providers can use these tools safely and effectively in real-world care settings.” – Oz in one press release

CMS Innovation Center Director Abe Sutton added that “the initiative gives providers in certain models another tool — with necessary safeguards — to support their patients’ needs by consulting on whether the potential use of hemp products could help improve symptoms.”

The program is subject to ia suit brought by a coalition of health advocacy organizations and anti-cannabis groups that argues it violates the Social Security Act, which “does not permit CMS to sanction the possession and use of illegal and dangerous Schedule I substances by Medicare patients without express authorization from Congress.”

TG joined Ganjapreneur in 2014 as a news writer and began hosting the Ganjapreneur podcast in 2016. He is based in upstate New York, where he also teaches media at a local university.

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media